Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The role of an iNOS polymorphism at the post-diagnosis diabetes development in children with Type 1 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{72a021aed8004e8ea7df0333367eb4b9,
title = "The role of an iNOS polymorphism at the post-diagnosis diabetes development in children with Type 1 diabetes",
abstract = "Objective: A missense polymorphism (rs2297518) of the inducible nitric oxide synthase (iNOS) gene causing a serine to leucine substitution at amino acic position 608 has previously been associated to the development of type 1 diabetes (T1DM). Activation of iNOS is a main effector pathway in cytokine mediated beta-cell destruction. Here, we evaluate whether rs2297518 associates to interleukin-1β (IL-1β) levels, metabolic control and development of autoantibodies 12 months post-diagnosis. Materials and Methods: The International Hvidoere cohort includes 275 children from 18 paediatric centers. The rs2297518 was tested in 256 participants and analyzed for its association to serum IL-1β levels, concentration of autoantibodies and residual beta-cell function as assessed by stimulated C-peptide, HbA1c and calculated insulin dose adjusted HbA1c (IDAA1c) at 1, 6 and 12 months post-diagnosis. Results: At 1 month IL-1β was detected more frequently in CC-genotype individuals as compared to CT and TT individuals, 24/168 vs. 3/75 and 0/9, respectively (p=0.03). This effect was not present at 6 and 12 months post-diagnosis. The iNOS polymorphism was not associated to diabetic ketoacidosis status at diagnosis, stimulated C-peptide, measured HbA1c levels or the calculated IDAA1c at any time point during the first 12 months post-diagnosis. Conclusion: The rs2297518 polymorphism of the iNOS gene may be involved in circulating IL-1β levels after diagnosis. However, this polymorphism does not seem to influence the metabolic outcome the first 12 months after diagnosis.",
author = "Jesper Johannesen and Vibeke Eriksen and Andersen, {Marie Louise Max} and Nielsen, {Lotte Br{\o}ndum} and Jannet Svensson and Regine Bergholdt and Flemming Pociot and Mortensen, {Henrik Bindesb{\o}l}",
year = "2016",
language = "English",
volume = "2",
journal = "Journal of Endocrinology and Diabetes Research",
number = "2",

}

RIS

TY - JOUR

T1 - The role of an iNOS polymorphism at the post-diagnosis diabetes development in children with Type 1 diabetes

AU - Johannesen, Jesper

AU - Eriksen, Vibeke

AU - Andersen, Marie Louise Max

AU - Nielsen, Lotte Brøndum

AU - Svensson, Jannet

AU - Bergholdt, Regine

AU - Pociot, Flemming

AU - Mortensen, Henrik Bindesbøl

PY - 2016

Y1 - 2016

N2 - Objective: A missense polymorphism (rs2297518) of the inducible nitric oxide synthase (iNOS) gene causing a serine to leucine substitution at amino acic position 608 has previously been associated to the development of type 1 diabetes (T1DM). Activation of iNOS is a main effector pathway in cytokine mediated beta-cell destruction. Here, we evaluate whether rs2297518 associates to interleukin-1β (IL-1β) levels, metabolic control and development of autoantibodies 12 months post-diagnosis. Materials and Methods: The International Hvidoere cohort includes 275 children from 18 paediatric centers. The rs2297518 was tested in 256 participants and analyzed for its association to serum IL-1β levels, concentration of autoantibodies and residual beta-cell function as assessed by stimulated C-peptide, HbA1c and calculated insulin dose adjusted HbA1c (IDAA1c) at 1, 6 and 12 months post-diagnosis. Results: At 1 month IL-1β was detected more frequently in CC-genotype individuals as compared to CT and TT individuals, 24/168 vs. 3/75 and 0/9, respectively (p=0.03). This effect was not present at 6 and 12 months post-diagnosis. The iNOS polymorphism was not associated to diabetic ketoacidosis status at diagnosis, stimulated C-peptide, measured HbA1c levels or the calculated IDAA1c at any time point during the first 12 months post-diagnosis. Conclusion: The rs2297518 polymorphism of the iNOS gene may be involved in circulating IL-1β levels after diagnosis. However, this polymorphism does not seem to influence the metabolic outcome the first 12 months after diagnosis.

AB - Objective: A missense polymorphism (rs2297518) of the inducible nitric oxide synthase (iNOS) gene causing a serine to leucine substitution at amino acic position 608 has previously been associated to the development of type 1 diabetes (T1DM). Activation of iNOS is a main effector pathway in cytokine mediated beta-cell destruction. Here, we evaluate whether rs2297518 associates to interleukin-1β (IL-1β) levels, metabolic control and development of autoantibodies 12 months post-diagnosis. Materials and Methods: The International Hvidoere cohort includes 275 children from 18 paediatric centers. The rs2297518 was tested in 256 participants and analyzed for its association to serum IL-1β levels, concentration of autoantibodies and residual beta-cell function as assessed by stimulated C-peptide, HbA1c and calculated insulin dose adjusted HbA1c (IDAA1c) at 1, 6 and 12 months post-diagnosis. Results: At 1 month IL-1β was detected more frequently in CC-genotype individuals as compared to CT and TT individuals, 24/168 vs. 3/75 and 0/9, respectively (p=0.03). This effect was not present at 6 and 12 months post-diagnosis. The iNOS polymorphism was not associated to diabetic ketoacidosis status at diagnosis, stimulated C-peptide, measured HbA1c levels or the calculated IDAA1c at any time point during the first 12 months post-diagnosis. Conclusion: The rs2297518 polymorphism of the iNOS gene may be involved in circulating IL-1β levels after diagnosis. However, this polymorphism does not seem to influence the metabolic outcome the first 12 months after diagnosis.

M3 - Journal article

VL - 2

JO - Journal of Endocrinology and Diabetes Research

JF - Journal of Endocrinology and Diabetes Research

IS - 2

M1 - 100114

ER -

ID: 49899852